Review

cd34 microbead kit ultrapure, human (Miltenyi Biotec)

Miltenyi Biotec is a verified supplier

Miltenyi Biotec manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Miltenyi Biotec cd34 microbead kit ultrapure, human
Cd34 Microbead Kit Ultrapure, Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 290 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34+microbead+kit+ultrapure/CD34+MicroBead+Kit+UltraPure%2C+human/custom%40130-100-453%4042603588
Average 96 stars, based on 290 article reviews

cd34 microbead kit ultrapure, human - by Bioz Stars, 2026-10

96/100 stars

Images

Isolation:

Article Title: Agents and methods for treating CBP-dependent cancers
Article Snippet: .. Mononuclear cells were isolated from cord blood using Ficoll-Paque PLUS density centrifugation and enriched for CD34+ cells using the CD34 MicroBead Kit UltraPure, according to the manufacturer's instructions (Miltenyi Biotech). ..

Article Title: IKAROS regulates human T cell phenotype at a thymic and postthymic level
Article Snippet: After 20–24 hours, cell supernatants were collected and analyzed for luciferase activity (Genecopoeia, catalog LF032) according to the manufacturer’s protocol. .. The ATOs were generated by aggregating a DLL4-expressing stromal cell line (MS5-hDLL4) with CD34 + cells isolated from fresh peripheral blood of a healthy individual and cryopreserved peripheral blood of patients carrying IKZF1 mutations, using the CD34 Microbead kit Ultrapure (Miltenyi Biotech) on the Auto MACS Pro Separator. ..

Article Title: IKAROS regulates human T cell phenotype at a thymic and postthymic level.
Article Snippet: .. The ATOs were generated by aggregating a DLL4-expressing stromal cell line (MS5-hDLL4) with CD34+ cells isolated from fresh peripheral blood of a healthy individual and cryopreserved peripheral blood of patients carrying IKZF1 mutations, using the CD34 Microbead kit Ultrapure (Miltenyi Biotech) on the Auto MACS Pro Separator. ..

Article Title: Therapy-Induced Clonal Selection as a Driver of Response to JAK Inhibitors in Myelofibrosis
Article Snippet: .. PBMCs were isolated via density-gradient centrifugation using Lympholyte-H (Cedarlane, Burlington, Canada), while CD34+ cells were immunomagnetically sorted using CD34 MicroBead Kit UltraPure (Miltenyi Biotec, Bergisch Gladbach, Germany). ..

Centrifugation:

Generated:

Magnetic Cell Separation:

Lysis:

Article Title: Invasion and development of Plasmodium falciparum in erythroblasts of humans carrying G6PD viangchan.
Article Snippet: .. Contaminating erythrocytes were eliminated by resuspending the cell pellet in lysis buffer (155 mM NH4Cl, 10 mM NaHCO3, and 0.1 mM EDTA in sterile distilled water) and incubating at 4 ◦C for 5 min. After an additional wash with 1X PBS, the cell suspension was processed for isolating CD34-positive cells using the CD34 MicroBead Kit UltraPure (Miltenyi Biotec, Germany), following the manufacturer's instructions. ..

Sterility:

Suspension:

Selection:

Article Title: Inherited human TFIIIA deficiency disrupts T cell development
Article Snippet: For FACS-based enrichment, CD34 + Lin − cells were sorted on a BD FACSAria Fusion (BD biosciences), with lineage-negative (Lin − ) being defined as negative for CD3, CD14, CD19, and CD56 expression. .. Magnetic enrichment was performed using either the EasySep Human Cord Blood CD34 Positive Selection Kit (Stemcell Technologies; 17896) or the CD34 MicroBead Kit UltraPure (Miltenyi Biotec) on an AutoMACS Pro Separator (Miltenyi Biotec), according to the manufacturer’s instructions. ..

Purification:

Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development
Article Snippet: .. Leukocytes from UCB and mPB were first purified using the Erythrocyte Sedimentation Kit II (Miltenyi), followed by CD34 + cell enrichment with the CD34 MicroBead Kit UltraPure (Miltenyi) per manufacturer’s instructions. .. For depletion of lymphoid precursor cells, UCB leukocytes were labeled with a cocktail of biotinylated lineage-specific (Lin) antibodies and CD10-biotin antibodies (Miltenyi, clone REA877/97C5, 1 μL/107 cells) for 10 min at 4°C.

Sedimentation:

Image Search Results

B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

Journal: Cell Reports Medicine

Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

doi: 10.1016/j.xcrm.2026.102879

Figure Lengend Snippet: B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

Article Snippet: Leukocytes from UCB and mPB were first purified using the Erythrocyte Sedimentation Kit II (Miltenyi), followed by CD34 + cell enrichment with the CD34 MicroBead Kit UltraPure (Miltenyi) per manufacturer’s instructions.

Techniques: Expressing

NOX1i in Myeloid-HIS-HCC mice reduces monocyte and tumor-associated macrophage infiltration. (A) Schematic overview of the experimental set-up. Male NSG-SGM3 mice (n = 11) were sublethally irradiated and the immune system was partly reconstituted using human cord blood (CB)-derived hematopoietic stem and progenitor cells (HSPCs). Four weeks post humanization, orthotopic human HCC was induced and mice were treated with 50 µM ML171 (NOX1i; n = 6) or vehicle (n = 5), twice per week for 3 weeks. (B) Human-to-murine immune cell (CD45) chimerism in the indicated tissues. (C) Human engraftment based on the number of human CD45 cells. Data are represented as violin plots showing median and quartiles. (D,E) Human immune cell subsets (D) and monocyte subsets (E) in indicated tissues represented as percentage of human CD45 cells. (F) Number of human macrophages and monocytes in the indicated tissues. (G) Representative immunohistochemistry images of infiltrated human monocytes/macrophages in liver tissue of HCC-bearing humanized mice. Sections were stained for human CD14 (brown), or matched IgG control. Scale bars: 100 µm. (B,D,E) . Data are shown as mean (SD). (C–E) Adjusted p-values were calculated using multiple unpaired t-test with Holm-Šídák correction (D,E) , or p-values were calculated using unpaired t-test with Welch’s correction or unpaired Mann-Whitney U test based on normal distribution (C,E) . *p < 0.05. HCC: hepatocellular carcinoma, NOX1i: NOX1 inhibition, huCD45: human CD45, muCD45: murine CD45, NK = natural killer, DCs: dendritic cells.

Journal: Frontiers in Pharmacology

Article Title: Harnessing human immune system models to validate NADPH oxidase 1 inhibition as treatment for hepatocellular carcinoma

doi: 10.3389/fphar.2026.1808515

Figure Lengend Snippet: NOX1i in Myeloid-HIS-HCC mice reduces monocyte and tumor-associated macrophage infiltration. (A) Schematic overview of the experimental set-up. Male NSG-SGM3 mice (n = 11) were sublethally irradiated and the immune system was partly reconstituted using human cord blood (CB)-derived hematopoietic stem and progenitor cells (HSPCs). Four weeks post humanization, orthotopic human HCC was induced and mice were treated with 50 µM ML171 (NOX1i; n = 6) or vehicle (n = 5), twice per week for 3 weeks. (B) Human-to-murine immune cell (CD45) chimerism in the indicated tissues. (C) Human engraftment based on the number of human CD45 cells. Data are represented as violin plots showing median and quartiles. (D,E) Human immune cell subsets (D) and monocyte subsets (E) in indicated tissues represented as percentage of human CD45 cells. (F) Number of human macrophages and monocytes in the indicated tissues. (G) Representative immunohistochemistry images of infiltrated human monocytes/macrophages in liver tissue of HCC-bearing humanized mice. Sections were stained for human CD14 (brown), or matched IgG control. Scale bars: 100 µm. (B,D,E) . Data are shown as mean (SD). (C–E) Adjusted p-values were calculated using multiple unpaired t-test with Holm-Šídák correction (D,E) , or p-values were calculated using unpaired t-test with Welch’s correction or unpaired Mann-Whitney U test based on normal distribution (C,E) . *p < 0.05. HCC: hepatocellular carcinoma, NOX1i: NOX1 inhibition, huCD45: human CD45, muCD45: murine CD45, NK = natural killer, DCs: dendritic cells.

Article Snippet: Freshly isolated CB-derived PBMCs, isolated from CB as described for buffy coat, were enriched for HSPCs based on positive immunomagnetic selection of CD34 + expressing cells using the human CD34 MicroBead Kit UltraPure (Miltenyi Biotec, #130–100-453) according to manufacturer’s guidelines.

Techniques: Irradiation, Derivative Assay, Immunohistochemistry, Staining, Control, MANN-WHITNEY, Inhibition

CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

Journal: Oncoimmunology

Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

doi: 10.1080/2162402X.2026.2695692

Figure Lengend Snippet: CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

Article Snippet: CD34 + cells were isolated with the MACS CD34 Microbead kit Ultrapure (130-100-453, Miltenyi Biotec).

Techniques: Derivative Assay, Generated, Isolation, Expressing, Cell Culture, Marker, Flow Cytometry

CD34-derived cDC1s and cDC2s are endocytic and exhibit antigen-presenting capacity. (A) Dot plots showing the percentage of cDC1s and cDC2s positive for CTV signal, indicative of CTV-labeled tumor cell uptake. (B) The scatter dot plot shows the frequency of tumor cell uptake positive DCs (identified as the percentage of CTV positive cDC1s and cDC2s) (mean ± SEM). (C) Representative histograms showing the percentage of cDC1s and cDC2s positive for Alexa647, indicative of active Dextran-Alexa647 uptake. (D) Scatter dot plot displaying the active dextran uptake (mean ± SEM). (E) Representative dot plots showing the frequency of proliferating autologous CFSE-labeled pan T-cells (indicated by the low CFSE expression) upon coculture with either untreated, TT-stimulated, or CMV-stimulated cDC1s for 6 d. (F) Scatter dot displaying the mean ± SEM of the percentage of autologous proliferating T-cells upon coculture with cDC2s (blue) and cDC1s (red) for 6 d under the indicated antigenic stimuli. (G) Scatter dot showing the mean ± SEM of the raw concentration of IFNγ and IL-2 detected by Luminex assay on supernatants collected after 6 d of cDC1 and cDC2 coculture with autologous T-cells together with the indicated antigenic stimuli. Statistical significance during uptake assays was calculated with either an unpaired t-test or a Mann–Whitney test. Statistical significance across antigen-specific assays was determined with Kruskal–Wallis test for the multiple comparison. * P < 0.05; ** P < 0.01; *** P < 0.001.

Journal: Oncoimmunology

Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

doi: 10.1080/2162402X.2026.2695692

Figure Lengend Snippet: CD34-derived cDC1s and cDC2s are endocytic and exhibit antigen-presenting capacity. (A) Dot plots showing the percentage of cDC1s and cDC2s positive for CTV signal, indicative of CTV-labeled tumor cell uptake. (B) The scatter dot plot shows the frequency of tumor cell uptake positive DCs (identified as the percentage of CTV positive cDC1s and cDC2s) (mean ± SEM). (C) Representative histograms showing the percentage of cDC1s and cDC2s positive for Alexa647, indicative of active Dextran-Alexa647 uptake. (D) Scatter dot plot displaying the active dextran uptake (mean ± SEM). (E) Representative dot plots showing the frequency of proliferating autologous CFSE-labeled pan T-cells (indicated by the low CFSE expression) upon coculture with either untreated, TT-stimulated, or CMV-stimulated cDC1s for 6 d. (F) Scatter dot displaying the mean ± SEM of the percentage of autologous proliferating T-cells upon coculture with cDC2s (blue) and cDC1s (red) for 6 d under the indicated antigenic stimuli. (G) Scatter dot showing the mean ± SEM of the raw concentration of IFNγ and IL-2 detected by Luminex assay on supernatants collected after 6 d of cDC1 and cDC2 coculture with autologous T-cells together with the indicated antigenic stimuli. Statistical significance during uptake assays was calculated with either an unpaired t-test or a Mann–Whitney test. Statistical significance across antigen-specific assays was determined with Kruskal–Wallis test for the multiple comparison. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: CD34 + cells were isolated with the MACS CD34 Microbead kit Ultrapure (130-100-453, Miltenyi Biotec).

Techniques: Derivative Assay, Labeling, Expressing, Concentration Assay, Luminex, MANN-WHITNEY, Comparison

CD34-derived cDC1s and cDC2s induce tumor-derived antigen-specific CD8 T-cell clones. To address the capacity of these DCs to prime the induction of a T-cell clone specific against the tumor antigen MART1, matured CD34-derived pan-DCs (combined cDC1s and cDC2s) loaded with the MART1-derived peptide were cultured with autologous naive CD8 T-cells. (A) Schematic representation of the experimental layout. (B) Representative dot plot showing the frequency of MART1-positive CD8 T-cells after the induction protocol with CD34-derived pan-DCs, as indicated by the abundance of dextramer-PE positive CD8 T-cell. (C) Before–after dot plots showing the frequency of MART1-specific dextramer-stained CD8 T-cells for each donor compared to a negative control dextramer. Each dot represents an individual donor ( n = 4). (D) Schematic representation of the rechallenge experimental layout. To address the responsiveness of induced MART1-specific T-cells to a secondary antigen rechallenge, MART1-loaded autologous moDCs were cocultured overnight with the earlier primed CD8 T-cell pool containing the MART1-specific CD8 T-cells. (E) Representative dot plots showing the expression levels of CD137 and CD25 on CD8 T-cells cocultured with either unloaded or MART1-loaded moDCs. (F) Before–after dot plots showing the frequency of positive CD8 T-cells for the simultaneous expression of CD25 and CD137. (G) Before–after dot plots showing the frequency of positive CD8 T-cells for the activation marker CD25, CD137, CD69, CD107a, and the intracellular cytokines IFNγ, IL-2, and TNFα after coculture with either unloaded or MART1-loaded moDCs. Each dot represents an individual donor ( n = 4). Statistical significance was calculated using either a paired t-test or a Wilcoxon test. P- values are numerically depicted in the graph.

Journal: Oncoimmunology

Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

doi: 10.1080/2162402X.2026.2695692

Figure Lengend Snippet: CD34-derived cDC1s and cDC2s induce tumor-derived antigen-specific CD8 T-cell clones. To address the capacity of these DCs to prime the induction of a T-cell clone specific against the tumor antigen MART1, matured CD34-derived pan-DCs (combined cDC1s and cDC2s) loaded with the MART1-derived peptide were cultured with autologous naive CD8 T-cells. (A) Schematic representation of the experimental layout. (B) Representative dot plot showing the frequency of MART1-positive CD8 T-cells after the induction protocol with CD34-derived pan-DCs, as indicated by the abundance of dextramer-PE positive CD8 T-cell. (C) Before–after dot plots showing the frequency of MART1-specific dextramer-stained CD8 T-cells for each donor compared to a negative control dextramer. Each dot represents an individual donor ( n = 4). (D) Schematic representation of the rechallenge experimental layout. To address the responsiveness of induced MART1-specific T-cells to a secondary antigen rechallenge, MART1-loaded autologous moDCs were cocultured overnight with the earlier primed CD8 T-cell pool containing the MART1-specific CD8 T-cells. (E) Representative dot plots showing the expression levels of CD137 and CD25 on CD8 T-cells cocultured with either unloaded or MART1-loaded moDCs. (F) Before–after dot plots showing the frequency of positive CD8 T-cells for the simultaneous expression of CD25 and CD137. (G) Before–after dot plots showing the frequency of positive CD8 T-cells for the activation marker CD25, CD137, CD69, CD107a, and the intracellular cytokines IFNγ, IL-2, and TNFα after coculture with either unloaded or MART1-loaded moDCs. Each dot represents an individual donor ( n = 4). Statistical significance was calculated using either a paired t-test or a Wilcoxon test. P- values are numerically depicted in the graph.

Article Snippet: CD34 + cells were isolated with the MACS CD34 Microbead kit Ultrapure (130-100-453, Miltenyi Biotec).

Techniques: Derivative Assay, Clone Assay, Cell Culture, Staining, Negative Control, Expressing, Activation Assay, Marker

Impaired proliferation and enucleation of erythroid cells derived from newly diagnosed multiple myeloma patients with anemia (NDMM-A)-CD34 + cells in vitro . (A) Schematic diagram of the three-phase in vitro erythroid differentiation culture system. (B) Growth kinetics of erythroid cells derived from CD34 + hematopoietic stem/progenitor cells of HDs and NDMM-A patients during in vitro differentiation. (C) Apoptosis analysis during erythroid differentiation. (C-a) Representative flow cytometry plots of Annexin V/7AAD staining on cultured day 7. (C-b) Quantitative analysis of Annexin V + rates (early and late apoptotic cells) at the indicated time points. (D) Quantitative analysis of GPA + percentage on different culture days. (E-a) Representative flow cytometry profiles of Hoechst33342 staining on cultured day 15; (E-b) Quantitative assessment of enucleation rates at different culture time points. (F) Representative images showing morphological features of erythroblasts on cultured day 15. Scale bar: 20 μm.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients

doi: 10.3389/fcell.2026.1718025

Figure Lengend Snippet: Impaired proliferation and enucleation of erythroid cells derived from newly diagnosed multiple myeloma patients with anemia (NDMM-A)-CD34 + cells in vitro . (A) Schematic diagram of the three-phase in vitro erythroid differentiation culture system. (B) Growth kinetics of erythroid cells derived from CD34 + hematopoietic stem/progenitor cells of HDs and NDMM-A patients during in vitro differentiation. (C) Apoptosis analysis during erythroid differentiation. (C-a) Representative flow cytometry plots of Annexin V/7AAD staining on cultured day 7. (C-b) Quantitative analysis of Annexin V + rates (early and late apoptotic cells) at the indicated time points. (D) Quantitative analysis of GPA + percentage on different culture days. (E-a) Representative flow cytometry profiles of Hoechst33342 staining on cultured day 15; (E-b) Quantitative assessment of enucleation rates at different culture time points. (F) Representative images showing morphological features of erythroblasts on cultured day 15. Scale bar: 20 μm.

Article Snippet: Hematopoietic stem/progenitor cells (HSPCs) were isolated using the Ultrapure CD34 Microbeads kit (Miltenyi Biotec, No. 130–100–453) according to the manufacturer’s protocol.

Techniques: Derivative Assay, In Vitro, Flow Cytometry, Staining, Cell Culture

Analysis of erythroid progenitor cells in the bone marrow of controls and newly diagnosed multiple myeloma patients with anemia. (NDMM-A) (A) Representative flow cytometry gating strategy for identifying erythroid progenitor cells in bone marrow samples from healthy donors (HDs), NDMM patients without anemia (NDMM-non anemia), and NDMM patients with anemia (NDMM-A). (B) Quantification of the percentage of erythroid progenitor cells in bone marrow mononuclear cells (MNC cells) from HDs, NDMM-non anemia, and NDMM-A patients (n = 10). *** P < 0.001. (C) (a) The number of BFU-E colonies in 5 × 10 4 BM cells; (b) The number of CFU-E colonies in 5 × 10 4 BM cells. (D) Representative images of BFU-E and CFU-E colonies (scale bar: 100 μm). (E) (a) The number of cells in one BFU-E colony; (b) The number of cells in one CFU-E colony.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients

doi: 10.3389/fcell.2026.1718025

Figure Lengend Snippet: Analysis of erythroid progenitor cells in the bone marrow of controls and newly diagnosed multiple myeloma patients with anemia. (NDMM-A) (A) Representative flow cytometry gating strategy for identifying erythroid progenitor cells in bone marrow samples from healthy donors (HDs), NDMM patients without anemia (NDMM-non anemia), and NDMM patients with anemia (NDMM-A). (B) Quantification of the percentage of erythroid progenitor cells in bone marrow mononuclear cells (MNC cells) from HDs, NDMM-non anemia, and NDMM-A patients (n = 10). *** P < 0.001. (C) (a) The number of BFU-E colonies in 5 × 10 4 BM cells; (b) The number of CFU-E colonies in 5 × 10 4 BM cells. (D) Representative images of BFU-E and CFU-E colonies (scale bar: 100 μm). (E) (a) The number of cells in one BFU-E colony; (b) The number of cells in one CFU-E colony.

Techniques: Flow Cytometry

Transcriptomic analyses of bone marrow erythroid progenitor cells in healthy donors (HDs) and newly diagnosed multiple myeloma patients with anemia (NDMM-A). (A) Volcano plot showing differentially expressed genes in erythroid progenitors between HDs and NDMM-A. (B) Heatmap of DEGs in erythroid progenitor cells from HDs and NDMM-A. (C) The top 10 upregulated pathways in NDMM-A erythroid progenitor cells. (D) The top 10 downregulated pathways in NDMM-A erythroid progenitor cells. (E) Expression levels (FPKM) of key markers involved in regulating early-stage erythropoiesis were compared in erythroid progenitor cells from HDs and NDMM-A patients. (F) Cell cycle analysis of erythroid progenitor cells from HDs and NDMM-A, as measured by EdU incorporation via flow cytometry. (G) Expression levels (FPKM) of erythropoiesis-related regulatory markers in erythroid progenitors from HDs and NDMM patients. NS: Not Significant. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients

doi: 10.3389/fcell.2026.1718025

Figure Lengend Snippet: Transcriptomic analyses of bone marrow erythroid progenitor cells in healthy donors (HDs) and newly diagnosed multiple myeloma patients with anemia (NDMM-A). (A) Volcano plot showing differentially expressed genes in erythroid progenitors between HDs and NDMM-A. (B) Heatmap of DEGs in erythroid progenitor cells from HDs and NDMM-A. (C) The top 10 upregulated pathways in NDMM-A erythroid progenitor cells. (D) The top 10 downregulated pathways in NDMM-A erythroid progenitor cells. (E) Expression levels (FPKM) of key markers involved in regulating early-stage erythropoiesis were compared in erythroid progenitor cells from HDs and NDMM-A patients. (F) Cell cycle analysis of erythroid progenitor cells from HDs and NDMM-A, as measured by EdU incorporation via flow cytometry. (G) Expression levels (FPKM) of erythropoiesis-related regulatory markers in erythroid progenitors from HDs and NDMM patients. NS: Not Significant. * P < 0.05, ** P < 0.01, *** P < 0.001.

Techniques: Expressing, Cell Cycle Assay, Flow Cytometry

Review

cd34 microbead kit ultrapure, human (Miltenyi Biotec)

Structured Review

Images

Related Articles

Isolation:

Centrifugation:

Generated:

Magnetic Cell Separation:

Lysis:

Sterility:

Suspension:

Selection:

Purification:

Sedimentation:

Similar Products

Image Search Results